🔍 Ovarian cancer often remains undetected until it's advanced, making personalized treatment critical. Myriad Genetics' oncology portfolio—featuring MyRisk® germline testing, MyChoice® CDx for HRD, and Precise® Tumor genomic testing—provides comprehensive results to personalize
Mark your calendars! 📅 Myriad Genetics will be at the NPWH Conference in Chicago from September 25-28. Don’t miss our booth for the latest in genetic testing and women’s health.
#NPWH2024
#genetics
#event
#healthcareprofessionals
After an MRI and biopsy, it was the Prolaris® report that provided the crucial insight: a 1.3% chance of dying from
#prostatecancer
in the next 10 years. This key information gave him the confidence to pursue active surveillance.
View his story
Curious about the latest research being presented at
#NSGC24
? 🔬
Don't miss the opportunity to explore our recent clinical developments highlighted in 10 innovation-focused, research-backed posters and platform presentations.
#NSGC24
#geneticresearch
#innovations
#research
💡 Our MyChoice® CDx comprehensive HRD test is the only commercial companion diagnostic included in
@ASCO
's recommendations for the use of PARP inhibitors.
Discover the advantages and pair MyRisk® germline testing, MyChoice® CDx for HRD testing, and Precise® Tumor genomic
We are thrilled to officially welcome Jennifer Fox as our Chief Legal Officer. Her
#leadership
will be instrumental in guiding our legal strategy & supporting Myriad's mission to advance health and well-being for all.
Learn more:
#teamMyriad
#welcome
Prolaris® testing helps personalize treatment plans by identifying if a patient is a candidate for active surveillance, or if they should pursue treatment like surgery or radiation, or a combination.
#ProstateCancerAwarenessMonth
As new FDA guidelines take effect, breast imaging facilities will be required to inform patients if they have dense breasts – a vital step forward in supporting women to take charge of their health. 💪
Our MyRisk® Hereditary Cancer Test with RiskScore analyzes density, among
📣 📣 DenseBreast-info (DBI) 👏 applauds 👏 the implementation of a National Breast Density Reporting Standard. The Federal legislation goes into effect on September 10, 2024: all women must be told either "dense" or "not dense."
🌟 Proud to partner with Black Physicians of Utah (BPOU) for their recent Back to School Mental Health
#event
, where our team shared valuable insights on
#mentalhealth
management - including how GeneSight can help!
#healthequity
#anxiety
#teamMyriad
"We believe Prolaris has the best data for us in terms of actionable information as to who needs AS, who needs actual treatment and the intensity of the treatment. It's the only biomarker that we feel like has that information." - Dr. Angelo Baccala
We announced today that Myriad
#leadership
will participate in two upcoming investor healthcare conferences.
Learn more and find out where we'll be:
#events
#teamMyriad
📰 Thank you to our own Dr. Dale Muzzey, PhD, for contributing to this insightful piece by
@Inside_PM
and underscoring our dedication to advancing MRD research & enhancing patient care.
See the full article:
#teamMyriad
#oncology
#innovation
#cancercare
"The Prolaris® test is the only biomarker that provides a highly personal risk estimate of absolute risk reduction so the individual can really decide whether using or omitting ADT is right for them”. - Dr. Jonathan Tward, MD, PhD, FASTRO
Learn more:
🌟 Visit our team at
#EpicUGM
next week to discover our
#innovation
, how we're pioneering the future of
#genetictesting
and precision medicine, and how we can collaborate to transform healthcare.
Learn about our integration solutions:
🏆 Thanks again for all our employees, partners and the Myriad Genetics community for helping make our recognition in
@TIME
as one of America's Best Midsize Companies of 2024 possible.
If you haven't yet, see the full list:
#companyculture
#teamMyriad
While ADT can be effective at slowing the progression of
#prostatecancer
, it is often associated with side effects that can significantly diminish one’s quality of life. Prolaris® testing determines how much someone may benefit from ADT vs. the side effects.
#genetictesting
We announced financial results for our second quarter ended June 30, 2024 and raised our previously issued financial guidance on business performance for the full-year 2024.
Read more:
Our MyRisk Hereditary Cancer Test was featured by a local news affiliate as a crucial tool for identifying
#hereditarycancer
risks, emphasizing how this can inform care and help
#healthcareprofessionals
develop personalized treatment.
#genetictesting